Tetrahydroisoquinoline derivatives as PPAR-alpha activators
US6987118B2 · kind B2 · utility
2Cited by
1References
6Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 5, 2004 |
| Grant date | Jan 17, 2006 |
| Priority date | — |
| Expiry date | May 5, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P29/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.